FDA Clears AI-Powered Non-Invasive Skin Cancer Detector

The FDA cleared an artificial-intelligence (AI)-powered device designed to non-invasively detect skin cancer in the primary care setting, the agency announced on Tuesday.

Developer DermaSensor said the device uses AI-powered spectroscopy technology to non-invasively evaluate cellular and subcellular characteristics of a lesion for any of the three common skin cancers — melanoma, basal cell carcinoma, and squamous cell carcinoma. The wireless, handheld device then provides a result in real time using an FDA-cleared algorithm.

The device was evaluated in a study of 1,005 patients across 22 centers that showed the device had a 96% sensitivity in detecting skin cancers, while a negative result had a 97% chance of being benign for all skin cancers.

A companion clinical utility study with 108 physicians, found that use of the device decreased the number of missed skin cancers by half (from 18% to 9%).

According to the FDA, the device — which will be available by prescription — is indicated for the evaluation of skin lesions in patients 40 years and over, and to assist health care providers in determining whether to refer a patient to a dermatologist.

The device should be used on lesions already assessed as suspicious for skin cancer, the agency said, and not as a screening tool, nor as the sole diagnostic criterion or to confirm a diagnosis of skin cancer.

“The benefits are as much for dermatologists as they are for [primary care physicians],” the company said in a release. “DermaSensor is expected to improve primary care and dermatology collaboration, enabling better-prioritized referrals in addition to the referral of more patients with skin cancer.”

The FDA is requiring that the company conduct additional post-market clinical validation performance testing of the DermaSensor device in patients representative of the general population, including people who had limited representation of melanomas in the premarket studies.

Mike Bassett is a staff writer focusing on oncology and hematology. He is based in Massachusetts.

Upping Immunotherapy Activity; A Win for Lung Screening; Looming Drug Price Break?

Finding a way to dissociate the activity of effector T cells from regulatory T cells could make immune checkpoint inhibitors more effective in the 60%

June 14, 2024

Probe of Alzheimer’s Researcher Halted; Dementia and Triglycerides; Migraine Genes

City University of New York temporarily halted its probe into the alleged scientific misconduct of faculty member and Alzheimer’s researcher Hoau-Yan Wang, PhD, citing concerns

November 1, 2023

Trial evaluates purine P2X7 receptor antagonist JNJ-54175446 in patients with major depressive disorder

Researchers investigated the safety and pharmacokinetics of JNJ-54175446 in a double-blind, multicenter, randomized controlled trial (RCT).

July 31, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.